Haemonetics (HAE) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Within Haemonetics (HAE) Vascular Closure, growth is led by the opening of new accounts and increasing penetration to gain share in the top U.S. EP hospitals.
Investors are optimistic about Haemonetics (HAE), led by the impressive performance of Plasma and Hospital businesses.
The mean of analysts' price targets for Haemonetics (HAE) points to a 27.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analy

New Strong Buy Stocks for May 26th

10:20am, Friday, 26'th May 2023
HDELY, WIRE, HAE, GWW and MUSA have been added to the Zacks Rank #1 (Strong Buy) List on May 26, 2023.
Investors with an interest in Medical - Products stocks have likely encountered both Haemonetics (HAE) and Insulet (PODD). But which of these two stocks presents investors with the better value opport

Haemonetics Corporation: Premium Blood Play

01:20pm, Thursday, 18'th May 2023
Haemonetics Corporation is showing signs of operational momentum again post-pandemic. After a painful 2021, amidst fears of customer losses, Haemonetics Corporation shares and the company have shown a
Investors continue to reward Haemonetics with higher market valuations in 2023. Driving these trends are the firm's attractive underlying economic characteristics.
Amid a challenging economic environment, Haemonetics (HAE) delivers impressive fiscal fourth-quarter organic revenues, led by the stellar performance across the Plasma and Hospital business.
Haemonetics (HAE) came out with quarterly earnings of $0.77 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.65 per share a year ago.
Investors looking for stocks in the Medical - Products sector might want to consider either VAREX IMAGING (VREX) or Haemonetics (HAE). But which of these two companies is the best option for those loo
Investors with an interest in Medical - Products stocks have likely encountered both Haemonetics (HAE) and Stryker (SYK). But which of these two stocks offers value investors a better bang for their b
Investors are upbeat about Haemonetics (HAE) owing to impressive Plasma and Hospital business performance, with continued strength in the Hemostasis Management product line.
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Haemonetics (HAE), The Kroger Co. (KR), JOYY (YY) and Novo Nordisk (NVO) are poised to gain.
HAE vs. SYK: Which Stock Is the Better Value Option?
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE